Evidence map›Paper›PMID 42146053›Full record

ArticleFrontiers in microbiology2026

Aerosol inhalation of human IFN-α1b exhibits anti-RSV activity in mice and favorable pharmacokinetics/safety in cynomolgus monkeys.

Mingming Yang, Liping Guo, Yanran Wang, Jiangtao Bai, Xiaowen Liang, Jiahua Kuang, Hongjie Ma, Yang Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mingming Yang *Shenzhen Kexing Pharmaceutical Co., Ltd, Shenzhen, China.
Liping Guo *Department of Microbiology, School of Basic Medicine, Guangxi Medical University, Nanning, China.
Yanran Wang *Capital Center for Children's Health, Capital Medical University, Beijing, China.
Jiangtao BaiShenzhen Kexing Pharmaceutical Co., Ltd, Shenzhen, China.
Xiaowen LiangShenzhen Key Laboratory of Pathogen and Immunity, Shenzhen Clinical Research Center for Infectious Disease, State Key Discipline of Infectious Disease, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, China.
Jiahua KuangShenzhen Key Laboratory of Pathogen and Immunity, Shenzhen Clinical Research Center for Infectious Disease, State Key Discipline of Infectious Disease, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, China.
Hongjie MaShenzhen Kexing Pharmaceutical Co., Ltd, Shenzhen, China.
Yang YangShenzhen Key Laboratory of Pathogen and Immunity, Shenzhen Clinical Research Center for Infectious Disease, State Key Discipline of Infectious Disease, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections, while effective therapeutic options remain limited. This study investigated the antiviral efficacy, pharmacokinetics, and safety of aerosolized human interferon-α1b (IFN-α1b) as a potential treatment for RSV infection. Methods: The antiviral activity of IFN-α1b against RSV was evaluated Results: IFN-α1b inhibited RSV Conclusion: Aerosolized IFN-α1b demonstrates antiviral activity and favorable lung-targeted pharmacokinetics in preclinical models, supporting further investigation in clinical settings. It was associated with greater reduction in lung viral titers compared with ribavirin in this model while maintaining a favorable safety profile.

Indexed as

aerosol inhalationcynomolgus monkeyIFN-α1bpharmacokineticsrespiratory syncytial virus

Identifiers

PMID42146053
PMCPMC13171780

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.